Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 8/20 | 0.55 |
| ▸ | DYRK1B | Q9Y463 | 7/20 | 0.55 |
| ▸ | JAK2 | O60674 | 5/20 | 0.55 |
| ▸ | AURKA | O14965 | 3/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | FLT1 | P17948 | 3/20 | 0.55 |
| ▸ | KDR | P35968 | 3/20 | 0.55 |
| ▸ | CLK2 | P49760 | 3/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.55 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.55 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.55 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.55 |
| ▸ | RET | P07949 | 3/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.55 |
| ▸ | PAK4 | O96013 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | LTK | P29376 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30508312 | 1.00 | DYRK1A (0.55) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL1585882 | 0.78 | DYRK1B (0.44) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL16537147 | 0.78 | DYRK1B (0.44) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL1144888 | 0.78 | DYRK1B (0.44) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL1592867 | 0.78 | DYRK1B (0.44) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL1585981 | 0.78 | DYRK1A (0.45) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL3373929 | 0.77 | DYRK1B (0.43) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL12466822 | 0.76 | IDO1 (0.46) | DYRK1ADYRK1BJAK2AURKAMAP4K4 | |
| SCHEMBL30440210 | 0.76 | RET (0.38) | DYRK1AJAK2RETLRRK2PDPK1 | |
| SCHEMBL22582281 | 0.76 | IDO1 (0.46) | DYRK1AJAK2KDRRETLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072040-A1 | AZAINDAZOLE DERIVATIVES USEFUL AS HCN2 MODULATORS | MERCK SHARP & DOHME LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119654314-A | Heterocyclic amide and urea compounds as JAK2 inhibitors | 艾捷斯治疗公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-09-05 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-07-18 | — | — | US | disclosed |
| EP-4387965-A2 | ARYL SULFONYL COMPOUNDS AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| EP-4387609-A2 | ARYL SULFONYL (HYDROXY) PIPERIDINES AS CCR6 INHIBITORS | ChemoCentryx, Inc. (US) | 2024-06-26 | — | — | EP | disclosed |
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | AMGEN INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CHEMOCENTRYX, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-08-02 | — | — | US | disclosed |
| WO-2007059219-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2007059219-A1 | AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-24 | — | — | WO | disclosed |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | GARLAND STEPHEN | 2006-10-05 | — | — | US | disclosed |
| US-7109199-B2 | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | SMITHKLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | disclosed |
| WO-2003068773-A1 | PYRAZOLOPYRIDINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12018016-B2 | Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors | CCR6, CCR1, CCR4 | DYRK1A 4726/4885DYRK1B 4821/4885JAK2 371/4885 |
| US-20240294524-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS | PDK1, PDK2, PDK3 | DYRK1A 1795/4885DYRK1B 1939/4885JAK2 1504/4885 |
| US-20240239752-A1 | BICYCLIC HETEROAROMATIC INHIBITORS OF KLK5 | KLK5, KLK1, KLKB1 | DYRK1A 1689/4885DYRK1B 1644/4885JAK2 4437/4885 |
| US-20060223800-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES ADN ANTIDIABETICS | ADK, PDXK, GPR119 | DYRK1A 1135/4885DYRK1B 883/4885JAK2 2768/4885 |
| US-12012403-B2 | Aryl sulfonyl compounds as CCR6 inhibitors | CCR6, CCR1, CCR3 | DYRK1A 4791/4885DYRK1B 4799/4885JAK2 216/4885 |
| US-20070179177-A1 | Azaindazoles useful as inhibitors of kinases | PRKDC, MAP3K20, PRKACA | DYRK1A 465/4885DYRK1B 512/4885JAK2 137/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | DYRK1A 1841/4885DYRK1B 1519/4885JAK2 2163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.